

COBLAnCE - A COhort to study BLAdder CancEr

Head :Benhamou Simone, UMR-S 956

Last update : 05/16/2012 | Version : 3 | ID : 3096

General	
Identification	
Detailed name	A COhort to study BLAdder CancEr
Sign or acronym	COBLAnCE
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL n°912260 525/10/2012°, CPP Ile-de-France VII : CO-12-001 (01/02/2012)
General Aspects	
Medical area	Cancer research
Health determinants	Addictions Genetic Geography Healthcare system and access to health care services Lifestyle and behavior Medicine Nutrition Occupation Social and psychosocial factors
Keywords	Bladder cancer, urology, cancer research, cohort
Scientific investigator(s) (Contact)	
Name of the director	Benhamou
Surname	Simone
Address	INSERM U946 27 rue Juliette Dodu 75010 Paris
Phone	01 53 72 50 48
Email	simone.benhamou@inserm.fr
Unit	UMR-S 956

Organization	Inserm
Collaborations	
Funding	
Funding status	Public
Details	ANR "Investissements d'avenir -Grand emprunt"
Governance of the database	
Sponsor(s) or organisation(s) responsible	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM
Organisation status	Public
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Cases at the participating hospitals will be identified as soon as possible after diagnosis. Early identification will be achieved through active searches, involving periodic visits to the hospital departments in which cases are diagnosed or treated. Inclusion period will last 2 years. The local coordinator will maintain a record of the cases identified and will indicate the reasons for which patients were not interviewed or material not collected (e.g., refusal, treatment).
Database objective	
Main objective	1) To test the association between constitutional DNA polymorphism, environmental parameters, molecular subtype and clinical data. The inclusion of features of both the tumour and the host will

facilitate the discovery of tumourigenesis mechanisms, drugable targets and diagnostic and prognostic biomarkers.

2) To provide insight into the tumour progression knowledge and to help to identify biomarkers by the sequential sampling of recurrent tumors, plasma or urine from individual patients during follow_up.

3) To validate and extend our prior results regarding the molecular subtyping of bladder cancer on a large series of tumors collected prospectively.

4) To facilitate the transfer of study results into clinical practice thanks to the size and bladder cancer representativeness of the cohort.

5) To describe treatment patterns and to assess the direct and indirect costs of bladder cancer. The cost variability will be analyzed to identify the determinants of cost. This evaluation will pave the way for cost-benefit analyses of new biomarkers developed by the consortium.

6) To structure, at the national level, an interdisciplinary bladder cancer network including epidemiologists, bioinformaticians, health economists, molecular biologists, occupational physicians, pathologists and urologists, for coordinated and synergistic research actions and to make a significant contribution to a European multinational cohort and support international studies in genomics, in particular.

Inclusion criteria

Inclusion as soon as possible after diagnosis of bladder cancer in the 17 participating hospitals

Population type

Age

Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered

Sick population

Gender

Male
Woman

Geography area

National

Detail of the geography area

Metropolitan France

Data collection

Dates

Date of first collection (YYYY or MM/YYYY) 09/2012

Size of the database

Size of the database (number of individuals) [1000-10 000[individuals

Details of the number of individuals 2000 patients

Data

Database activity Current data collection

Type of data collected Clinical data
Declarative data
Biological data

Clinical data (detail) Direct physical measures

Details of collected clinical data DISEASE MANAGEMENT > Disease presentation: presence of symptoms (hematuria, pollakuria, dysuria, urgency, hydronephrosis), alteration of health status > Procedures before diagnostic resection: urinary cytology, urine culture, abdominal ultrasound, urinary tract fibroscopies, imaging (scanner, MRI) > Diagnosis through transurethral resection of the bladder: Hervix or Narrow-Band-Imaging fluorescence, number and location of resected tumors, size and aspect of the largest tumor > Treatment: for NMIBC: intravesical instillations and cystectomy; for MIBC: chemotherapy, radiotherapy, for both NMIBC and MIBC: lymphadenectomy, urethrectomy, nephro-urethrectomy, urinary diversion, blood transfusion, any hospitalization and complications > Outcomes: locoregional and distant recurrences (dates, sites, pathology, treatments, etc.) and death (date and place). PATHOLOGY > Histological type and subtype, prognostic factors, pathological review for all cases at initial diagnosis and in case of recurrence. quality of life > Generic measures (EuroQol EQ-5D-3L & EORTC QLQ-C30) > Specific measures (EORTC-BLS24 & EORTC-BLM30)

Declarative data (detail) Face to face interview

Details of collected declarative data EPIDEMIOLOGIE : - Sociodemographic characteristics: age, gender, place of birth, educational level, marital status, household income, working situation, history of residences and of occupations - Lifestyle: history of tobacco

consumption, dietary habits and physical activity >
 Medical history and medication use: weight, height, urinary tract infection, hematuria, kidney stones, skin or respiratory allergies, anti-hypercholesteremic and anti-inflammatory drugs, hormonal treatment, personal and family history of cancer.

Biological data (detail)

DNA, RNA, plasma, protein extracts from blood, tumors and/or urine

Presence of a biobank

Yes

Contents of biobank

Whole blood
 Serum
 Blood cells isolated
 Fluids (saliva, urine, amniotic fluid, ?)
 Tissues

Details of biobank content

Lymphocytes, plasma and red blood cells. Tumour tissues at first transurethral resection embedding in paraffin. If the tumour is sufficiently large, a sample will be snap-frozen and stored at -80°.

Health parameters studied

Health event/mortality
 Health care consumption and services
 Quality of life/health perception
 Others

Care consumption (detail)

Hospitalization
 Medical/paramedical consultation
 Medicines consumption

Other (detail)

LQ (Lifestyle questionnaire) : demographic details (age/sex/education/ place of residence/ social class), complete smoking history, history of drinking habits (water, coffee, tea, alcohol, etc), occupational history and physical activity, and personal medical history and familial history of cancer. ---- Economic questionnaire : all medical resources related to bladder cancer and their cost for each patient.

Procedures

Data collection method

Clinical data on the tumour present on inclusion will be obtained from the review of clinical charts by trained monitors. The clinical and pathologic data will include all EAU factors used to predict recurrence and progression (tumour size, multiplicity, stage, grade, associated CIS). All patients will undergo identical interviews, during which they will complete a lifestyle questionnaire (LQ) and quality of life

questionnaire (QOL). The lifestyle questionnaire is structured and will be used to collect the following information: demographic details (age/sex/education/place of residence/social class), complete smoking history, history of drinking habits (water, coffee, tea, alcohol, etc), occupational history and physical activity, and personal medical history and familial history of cancer. Health care resources use and quality of life data will be collected for each patient at baseline and every year during follow-up. Healthcare resource use will be collected both from the medical records in the participating centres and interviewing the patients by telephone. Each patient should give its consent to this data collection including access to national health insurance claims data. The economic questionnaire will be structured according the course of the disease (diagnosis, initial treatment, follow-up, recurrences, and progression including metastatic disease). All medical resources (inpatient - surgery, chemotherapy, etc?-, and, outpatient services and visits) related to bladder cancer will be collected for each patient and during the whole study period. Sick leaves will be collected on a yearly basis until the end of follow-up (e.g. 6 years after inclusion). Unit cost information will be gathered from official sources (mainly national health insurance) to cost each type of resources and compute direct and indirect costs. A special attention will be paid to innovative drugs and technologies including biomarkers research. All this information will be collected on specific structured logsheets.

Participant monitoring	Yes
------------------------	-----

Details on monitoring of participants	6 years
---------------------------------------	---------

Links to administrative sources	No
---------------------------------	----

Promotion and access

Promotion

Access

Presence of document that lists variables and coding procedures	Yes
---	-----

Terms of data access (charter for data provision, format of data, availability delay)	Terms are currently being defined
---	-----------------------------------

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only